#Bioretec #Finland #Tampere #RemeOs #Alan Donze

Bioretec Ltd Introduces CEO Stock Option Program

On March 21, 2025, the Board of Directors of Bioretec Ltd, a Finnish medical device company, officially launched a new stock option program for its CEO, Alan Donze. This strategic initiative aims to enhance shareholder value and aligns Donze’s interests with those of investors, fostering a commitment to the company's long-term success.

The Structure of the Option Program

The Board has approved a total issuance of 610,105 stock options to Donze, with each option giving him the right to acquire one share of Bioretec. The issuance of these options is provided at no cost whatsoever, a move that underscores Bioretec's confidence in its future growth prospects. Under the terms of the new program, the share subscription periods will unfold in two phases:

• - One third of the options can be exercised starting on May 20, 2025.
• - The remainder will become available in monthly installments starting June 20, 2025, continuing until the final shares can be subscribed by December 31, 2030.

The subscription price for the shares has been set at EUR 2.79, which was determined based on the average share price on Nasdaq Helsinki over a specified period. This price reflects a 10% increase from the average value assessed between December 20, 2024, and March 20, 2025. Shareholder dividends and other distributions will also account for adjustments in this subscription price.

Implications for Company Shares and Future Growth

The establishment of this option program is projected to potentially increase the liquidity of Bioretec's shares by up to 610,105 new shares, representing an increase of approximately 2.48% in total shares. Following this transaction, the company expects a more robust trading environment, allowing for greater participation from the investor community.

The theoretical market value of the options, calculated using the Black-Scholes model, has been estimated at around EUR 1.1357 per option, amounting to a total estimated value of nearly EUR 692,896. This economic architecture not only suggests monetary incentive for the CEO but also signals a strong operational trajectory for the entire organization.

Bioretec’s Market Position and Innovations

Bioretec is renowned for its pioneering work in biodegradable orthopedic implants. The firm is actively working to improve surgical outcomes through its RemeOs™ product line, recently authorized in the U.S. and granted CE mark approval in Europe. This line highlights Bioretec’s commitment to revolutionizing treatment protocols in orthopedic surgeries, with potential applications in the multi-billion dollar global orthopedic trauma and spine market. The innovative attributes of the RemeOs™ implants allow for natural bone substitution, mitigating the need for secondary removal surgeries and thereby improving patient care.

As Bioretec strides towards re-shaping healthcare paradigms within orthopedics, the new stock option program for Alan Donze may serve as not only an incentive for his leadership but also a catalyst for the company's ongoing innovations, enabling the firm to meet the increasing demands for quality healthcare solutions.

With a promise of better healing leading to a better life, Bioretec pursues its mission of enhancing quality of care through continuous development of its advanced implant technologies.

For media inquiries, you can reach out to Kustaa Poutiainen, Chairperson of the Board, at +358 40 042 4506.